Brief: Vicore's Air Study Interim Analysis Suggests That C21 Improves Lung Function In IPF Patients

Vicore Pharma Holding AB

10/02/2022 05:58

Feb 10 (Reuters) - Vicore Pharma Holding AB  VICOR.ST :
    * VICORE'S AIR STUDY INTERIM ANALYSIS SUGGESTS THAT C21
IMPROVES
LUNG FUNCTION IN IPF PATIENTS
    * C21 WAS SAFE AND WELL TOLERATED
    * PLANNING OF A PHASE 2B STUDY IS BEING INITIATED
    * BETWEEN 24 AND 36 WEEKS, FVC WAS EITHER STABLE OR
CONTINUED TO
INCREASE

Source text for Eikon:  ID:nWkr6K6w2C 
Further company coverage:  VICOR.ST 

 ((Reuters.briefs@thomsonreuters.com;))